Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Accenture
US Army
Julphar
McKinsey
Harvard Business School
Mallinckrodt
Merck
Chubb

Generated: September 18, 2018

DrugPatentWatch Database Preview

Otsuka Pharm Co Ltd Company Profile

« Back to Dashboard

What is the competitive landscape for OTSUKA PHARM CO LTD, and when can generic versions of OTSUKA PHARM CO LTD drugs launch?

OTSUKA PHARM CO LTD has five approved drugs.

There are forty-seven US patents protecting OTSUKA PHARM CO LTD drugs.

Summary for Otsuka Pharm Co Ltd
US Patents:47
Tradenames:5
Ingredients:4
NDAs:5

Drugs and US Patents for Otsuka Pharm Co Ltd

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Otsuka Pharm Co Ltd ABILIFY MAINTENA KIT aripiprazole FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 202971-003 Sep 29, 2014 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Otsuka Pharm Co Ltd ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202-003 Nov 13, 2017 RX Yes No 9,089,567 ➤ Try a Free Trial ➤ Try a Free Trial
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-002 Jul 10, 2015 RX Yes No 7,888,362 ➤ Try a Free Trial Y ➤ Try a Free Trial
Otsuka Pharm Co Ltd ABILIFY MAINTENA KIT aripiprazole FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 202971-001 Feb 28, 2013 RX Yes No 8,338,428 ➤ Try a Free Trial Y ➤ Try a Free Trial
Otsuka Pharm Co Ltd ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202-001 Nov 13, 2017 RX Yes No 8,718,193 ➤ Try a Free Trial Y ➤ Try a Free Trial
Otsuka Pharm Co Ltd ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202-002 Nov 13, 2017 RX Yes Yes 9,433,371 ➤ Try a Free Trial Y ➤ Try a Free Trial
Otsuka Pharm Co Ltd ABILIFY MAINTENA KIT aripiprazole FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 202971-002 Feb 28, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Otsuka Pharm Co Ltd

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Otsuka Pharm Co Ltd ABILIFY MAINTENA KIT aripiprazole FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 202971-004 Sep 29, 2014 5,006,528*PED ➤ Try a Free Trial
Otsuka Pharm Co Ltd ABILIFY MAINTENA KIT aripiprazole FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 202971-001 Feb 28, 2013 5,006,528*PED ➤ Try a Free Trial
Otsuka Pharm Co Ltd ABILIFY MAINTENA KIT aripiprazole FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 202971-002 Feb 28, 2013 5,006,528*PED ➤ Try a Free Trial
Otsuka Pharm Co Ltd ABILIFY MAINTENA KIT aripiprazole FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 202971-003 Sep 29, 2014 5,006,528*PED ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Non-Orange Book US Patents for Otsuka Pharm Co Ltd

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,006,248 5-HT.sub.1A receptor subtype agonist ➤ Try a Free Trial
8,802,183 Communication system with enhanced partial power source and method of manufacturing same ➤ Try a Free Trial
9,083,589 Active signal processing personal health signal receivers ➤ Try a Free Trial
9,387,207 5-HT1A receptor subtype agonist ➤ Try a Free Trial
9,439,566 Re-wearable wireless device ➤ Try a Free Trial
8,703,772 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof ➤ Try a Free Trial
9,480,686 Piperazine-substituted benzothiophenes for treatment of mental disorders ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Patents for Otsuka Pharm Co Ltd Drugs

Supplementary Protection Certificates for Otsuka Pharm Co Ltd Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2009 00031 Denmark ➤ Try a Free Trial
C/GB09/037 United Kingdom ➤ Try a Free Trial PRODUCT NAME: TOLVAPTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/09/539/001 20090803; UK EU/1/09/539/002 20090803; UK EU/1/09/539/003 20090803; UK EU/1/09/539/004 20090803
/2014 Austria ➤ Try a Free Trial PRODUCT NAME: ARIPIPRAZOL; REGISTRATION NO/DATE: EU/1/13/882 (MITTEILUNG) 20131119
9 5013-2014 Slovakia ➤ Try a Free Trial PRODUCT NAME: ARIPIPRAZOL; REGISTRATION NO/DATE: EU/1/13/882/001 - EU/1/13/882/004 20131119
0408 Netherlands ➤ Try a Free Trial 300408, 20101018, EXPIRES: 20151017
2014 00026 Denmark ➤ Try a Free Trial PRODUCT NAME: ARIPIPRAZOL; REG. NO/DATE: EU/1/13/882/001-004 20131115
0669 Netherlands ➤ Try a Free Trial PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
QuintilesIMS
Fuji
Argus Health
Covington
Citi
Daiichi Sankyo
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.